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Abstract
Background: Drug design against proteins to cure various diseases has been studied for several years. Numerous design
techniques were discovered for small organic molecules for specific protein targets. The specificity, toxicity and selectivity of
small molecules are hard problems to solve. The use of peptide drugs enables a partial solution to the toxicity problem.
There has been a wide interest in peptide design, but the design techniques of a specific and selective peptide inhibitor
against a protein target have not yet been established.
Methodology/Principal Findings: A novel de novo peptide design approach is developed to block activities of disease
related protein targets. No prior training, based on known peptides, is necessary. The method sequentially generates the
peptide by docking its residues pair by pair along a chosen path on a protein. The binding site on the protein is determined
via the coarse grained Gaussian Network Model. A binding path is determined. The best fitting peptide is constructed by
generating all possible peptide pairs at each point along the path and determining the binding energies between these
pairs and the specific location on the protein using AutoDock. The Markov based partition function for all possible choices
of the peptides along the path is generated by a matrix multiplication scheme. The best fitting peptide for the given surface
is obtained by a Hidden Markov model using Viterbi decoding. The suitability of the conformations of the peptides that
result upon binding on the surface are included in the algorithm by considering the intrinsic Ramachandran potentials.
Conclusions/Significance: The model is tested on known protein-peptide inhibitor complexes. The present algorithm
predicts peptides that have better binding energies than those of the existing ones. Finally, a heptapeptide is designed for a
protein that has excellent binding affinity according to AutoDock results.
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Introduction
The determination of a specific peptide sequence with affinity to
a particular protein surface is a problem of high degree of
complexity arising from the fact that each residue of the peptide
could be chosen from a pool of twenty natural amino acids. Even
for a peptide with three amino acid residues, there exist 8610
3
possible peptide sequences. Screening of such a large number of
molecules is complicated with both experimental and computa-
tional techniques. A rational methodology for specific and selective
peptide sequence prediction is required. The necessary method-
ology should be time-efficient and be able to design peptides for
given locations on a given set of proteins. A fast and global
computational tool is desired. The importance, computational and
experimental difficulties and the present state of the art of finding
new peptides have recently been discussed and reviewed by
Petsalaki et al. [1].
The complete peptide binding problem can be visualized as a
three step process: (i) finding a path on the surface of the protein
which defines a suitable region for the peptide to bind, (ii) finding
the appropriate peptide for this path, and (iii) improving the
peptide for a more stable binding required for inhibition. In some
cases, the binding surface is known, and a peptide must be
designed de novo. In other cases, a peptide is given and the best
region on the surface that gives the optimum binding conditions is
searched. The method of Petsalaki et al., based on a knowledge
based bioinformatics approach addressed this problem and could
successfully find the binding sites for the peptides. A similar
‘indirect’ design approach has been adopted by Frenkel et al. [2],
using their de novo molecular design computational tool Pro_
Ligand. Known peptides were docked to unknown locations on
given proteins by Hetenyi and Spoel [3] using AutoDock. There
have been successful attempts for computational peptide design
that use knowledge-based search strategies and use diverse sets of
statistical descriptors, different training databases, hydrophobicity
scales, motif regularities, etc. [4]. Also, automated peptide binding
search techniques [5,6,7] from known epitopes or protein libraries
have been successfully used as bioinformatics tools. There have
been applications of bioinformatics computational binding tools
such as the sequence moment concept, artificial neural networks,
fuzzy neural networks and Hidden Markov Model for checking
the suitability of inhibitory peptides for binding on MHC class II
proteins [4,8,9,10,11,12,13,14,15,16]. Along similar lines, the
suitability of a ligand as a drug was tested using Bayesian neural
network analysis [17]. Application of genetic algorithms to the
design of peptides has been an important line of research,
examples of which are: in silico peptide screening and application of
genetic algorithm to determine inhibitory peptide against
Parkinson’s-disease-related protein a-Synuclein [18]; peptides as
thrombin inhibitors [19,20]; evaluation of energies for peptide
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e10926binding to a user-defined protein surface patch via Genetic
algorithm for p53, oligopeptidase and DNA gyrase [21]; integer
linear programming [22]; design of hexapeptides against strome-
lysin protein by Singh et al. [23], and a peptide buildup approach
together with a genetic algorithm [24,25,26]. We have imple-
mented genetic algorithm and a Markov model for de novo
heptapeptide design in our recent study [27]. Most of the methods
cited in this paragraph use models that depend on structural
properties of the peptides and the peptide-protein complex. The
prior knowledge of the structural basis of peptide-protein binding
strategies is extremely important. The recent paper by London
et al. [28], that reviews these strategies is important for
understanding the basis of the works cited here. Important points
that should be taken into consideration in the sequential
generation of ligand molecules concerning the placement of
fragments on the surface are discussed by Pegg et al. [29].
Our method offers a novel procedure for de novo peptide design
that sequentially generates the peptide by docking its residues pair
by pair along a chosen path on a protein. We adopt three novel
approaches in our design: (i) The first one is the determination of
the binding site on a given protein which we determine using the
coarse grained Gaussian Network Model (GNM). Recently, we
showed that the GNM identifies the surface residues that are
suitable binding sites [30,31,32]. Once the binding region is
determined, we obtain the binding path on it by docking an
arbitrarily chosen peptide using AutoDock [33]. As will be
described below, this path is flexible and not very restrictive. (ii)
The second novel aspect of the model is the choice of the best
fitting peptide to this path. We generate all possible amino acid
pairs at each point along the path, calculate the binding energies
between these pairs and the specific location on the protein via
AutoDock, and form the statistical weight of each pair of amino
acids. Once all possible pairs are determined for the full path, we
form the Markov based partition function for all possible choices
of the peptides using the Ising model matrix multiplication scheme
[34]. We evaluate the transition probabilities based on this
partition function, and select the best peptide for the given surface
employing a Hidden Markov model (HMM) using Viterbi
decoding [35]. The types of amino acids are the hidden variables
of the algorithm to be obtained as the solution of the problem. (iii)
The third novel feature of our approach is the consideration of the
suitability of the conformations of the peptides that result upon
binding on the surface by including the intrinsic Ramachandran
potentials of the w2y angles [36]. These are the observables of the
Viterbi algorithm. As in the choice of the peptides, we assume that
the Ramachandran torsion angles obey Markov statistics accord-
ing to which a given torsion angle depends on the choice of the
preceding torsion angle.
The Viterbi algorithm is an efficient way of determining the best
state solution of a hidden Markov model based on a given
observation sequence [37,38] and is being used widely in the
analysis of biological data and in bioinformatics area [39]. Protein
structure prediction, where proteins are represented as Markov
states, utilizes the Viterbi algorithm. The methodologies are
summarized by Bystroff et al. [40]. Analysis of protein, RNA or
DNA sequences were also achieved by the Viterbi algorithm as
illustrated by a study on gene finding from DNA sequence by
Sramek et al. [41]. The prediction of the topology of all-beta
membrane proteins combining Viterbi and posterior algorithms
was proposed [42] as a modified Viterbi algorithm. Mirabeau
et al. determined novel peptide hormones by the Viterbi algorithm
by training their algorithm with known receptor protein peptide
hormone interactions and testing the model on peptide sequences
in databases [43]. A similar Viterbi algorithm was adopted by
Sonmez et al., [44]. Noguchi et al. employed the Viterbi algorithm
on 3 different studies for peptide design against MHC class II
proteins. Training was achieved by non-binding and binding
peptides of the target proteins and tests applied to different data-
set indicated that the method is able to predict binder peptide
sequences [11,14,16].
The plan of the paper is as follows: In the first part, we define
the methods needed for the Viterbi algorithm to run properly.
Firstly, we define the binding site and path selection procedure.
We then explain how the selected binding-path is partitioned into
n number of overlapping grids, where n is the desired peptide
length. Subsequently, the docking procedure of the 20 amino acids
for the first site and 400 dipeptides each of the succeeding n grids
on the binding-path are explained. The calculated binding energy
scores from the docking procedure are used to obtain the statistical
weights for the pair wise dependent choice of amino acids.
Knowing the weights, the partition function for a given sequence is
calculated using a matrix multiplication scheme and the transition
probabilities for each n grid are obtained. We define the various
regions on a Ramachandran map as the torsion states of the
residues. We then construct the probabilities of the torsion states of
a pair of neighboring residues using information from the Protein
Data Bank. Inasmuch as we are interested in the denatured
conformations of peptides, we construct a coil library from which
we obtain the probabilities of the torsion angles [45]. The bound
(docked) conformations of each dipeptide on each n grid are used
to obtain the torsion angle state of the dipeptide of interest which is
used to define the emission probabilities. In the second part of the
paper, implementation of the Viterbi algorithm to the peptide
binding problem is defined. In the final part, several examples are
given.
Methods
The Model
The model consists of five parts: (i) Determining the binding site
and the sequence of residues on the surface of the target protein on
which the peptide will be docked, (ii) determining the chiral
carbon positions of the n residue peptide that will be interacting
with the sequence of residues on the target protein surface, (iii)
partitioning the path of the n points into a sequence of grids, (iv)
docking, by using AutoDock, all 20 peptides to the first grid, and
all 400 dipeptides to the succeeding pairs of grids and evaluating
their binding affinities, (v) characterizing the w2y propensities of
the dipeptides. We then use the outcome of these five steps for the
implementation of the Viterbi algorithm.
Determining the binding site and the sequence of
residues on the target protein. The Gaussian network
model (GNM) has been shown to predict the protein residues
located at specific sites for drug binding [30,31,32]. We employed
GNM to predict ‘binding site residues’ that play major role in
peptide binding.
Having identified a site by the GNM, we then need a sequence
of residues on the protein that will be in contact with the binding
peptide. We choose this sequence of residues using either of the
following two approaches: (i) If the protein exists in complex with
other proteins, and if the site determined by the GNM lies in an
interface in the complex, then the complex is used to determine
this sequence of residues on the surface. Recently, two studies
indicated that protein-protein interactions, Tuncbag et al. [46]
and protein-peptide interactions, Vanhee et al. [47] adopt the
same structural motifs as monomeric protein folds. The existence
of specific folds at the interaction site increases the stability of the
formed protein-peptide complex. The counterpart fold of the
Peptide Design
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The protein crystal structure of the target protein is given as input
to the web-server HotPoint [48] which predicts the residues of
interest on the surface. In Figure 1 an example obtained from the
HotPoint server is given. In this specific example the target protein
Human Growth Hormone (HGH) is formed by helices and the
counterpart protein Human Growth Hormone Receptor (HGHR)
is formed by beta-strands. The binding site of HGH, determined
by the GNM, is depicted in pink and the residues that interact with
the HGH binding-site, determined by HotPoint, are in green. The
region shown in pink will contain the residues to which the peptide
will bind. The chiral carbons of the residues shown in green are
used as grid-centers for the peptide to be designed, which will be
explained in the next section. (ii) If an interacting partner of the
protein does not exist, a probe peptide made up of all alanine
residues, equal in number to the residues of the peptide to be
designed, is docked to the binding site using AutoDock. The
specific aim of docking an all alanine peptide is to obtain a path
which may well be approximated by the backbone contour.
Deviations from this path, due to the forces imposed by placing
bulky side groups as the peptide grows on the surface for example,
are accounted for as described below. The details of AutoDock
parameters are given in Appendix S1. Chiral carbon coordinates
of the docked peptide are essential for further steps.
Partitioning the Path into Grids. Our aim is to design a
peptide of n amino acids. For this purpose, we need n points –one
for the center of each amino acid of the peptide- that is close to the
sequence of residues on the binding surface. We choose these n
points as the spatial coordinates of the chiral carbons of either the
docked probe peptide or the interacting protein portion
determined by HotPoint. Once this path of n points is defined,
n contiguous grid boxes are constructed, each centered around
one of the n points. The first grid contains the first amino acid.
The first and the second grids along the path contain the first and
the second amino acids. The t
th and t+1
st grids contain the t
th and
t+1
st residues. The n chiral carbon atoms of the path define the
centers of the n grid boxes.
Docking of amino acids & dipeptides to the binding
site. The AutoDock program [33] is used as the docking tool to
quantify the binding affinity between the dipeptides and the
selected protein surface. Python scripts are written to automate the
docking, the probability calculation and the peptide sequence
determination procedures. The binding affinity of a given peptide
to the surface is determined via AutoDock which gives the affinity
in terms of binding energy in kcal/mol.
All 20 amino acids are docked to the 1
st grid of the pre-defined
path, such that their chiral carbon atoms are forced to coincide
with the first grid center. All 400 possible dipeptides are docked to
the first and second grid boxes, with the successive chiral carbons
located at the grid centers. The pair wise docking of the dipeptides
is continued in this way up to the last dipeptide along the path.
Pair wise docking rests on the assumption of the Markov property.
The amino acids and dipeptides are prepared by the HyperChem
software [49]. The dipeptides have Ace-cap on their N-termini.
The grid map is determined by the ADT subprogram of
AutoDock. The pre-determined spatial coordinates of the chiral
carbon atoms on the path are used as the AutoDock grid box
centers. The optimum grid box size is found by trial and error as
2.5 times the length of the distance between the first nitrogen and
the last carbon along the backbone of the amino acids. The grids
are set such that the chiral carbon atoms of the amino acid
coincide with the grid box centers but with a freedom to rotate and
translate in the box. This freedom, while keeping the dipeptides to
be constrained to the neighborhood of the chosen grids is
necessary to account for the side chain differences of the different
amino acids. It also decreases the entropy penalty of constraining a
peptide to a certain region. The parameters of AutoDock are given
in Appendix S2.
Docking the dipeptide on a given grid pair leads to a set of 400
binding affinities, one set for each dipeptide, which are used to
determine the probability of binding of each dipeptide to the
protein binding site as explained in the following section.
Calculation of transition probabilities. The 20 types of
amino acids and the peptide length n determine the number of
states in our model; there exists 20n states for the problem. For the
Markov model adopted here, one needs the transition
probabilities, i.e., the probability of an amino acid occupying the
t+1
st position, given the amino acid at the t
th location. The binding
energies of dipeptides obtained by AutoDock are used as the
statistical weights for determining the transition probabilities. We
adopt the Rotational Isomeric States (RIS) approach of polymer
physics which is well suited for this purpose [34,50,51]. For each
grid the probabilities are calculated via the formulation given
below by Eqs. 1, 2, 3, and 4. For the 1
st grid 20 binding energies
are available, while for the remaining grid pairs 400 binding
energies are available; the corresponding statistical weight matrix
is given in Eq.1 and 2, respectively. The RIS matrix multiplication
scheme [34] is used to determine probabilities from the energies.
The statistical weight matrix U1 for the amino acid bound to the
1
st grid box is
U1~exp bE1;i
  
ð1Þ
where b~1=kT, k being the Boltzmann constant and T the
temperature,iisanyofthe20aminoacids;alanine,cysteine,aspartic
Figure 1. Selection of path by HotPoint server. HGHR (on the left)
interacts with HGH (on the right): HotPoint predicts that the regions
indicated with green and pink colors interact. The green-colored HGHR
residues are selected as binding-sites. The pink-colored HGH residues
are selected as binding peptide path.
doi:10.1371/journal.pone.0010926.g001
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lysine, leucine, methionine, asparagine, proline, glutamine, arginine,
serine, threonine, valine, tryptophan, tyrosine.
The statistical weight matrix Utz1 for the dipeptide formed by
the t
th and t+1
st residues along the peptide is
Utz1~exp bEt,tz1;i,j
  
ð2Þ
where t, 1ƒtƒn{1 ðÞ , represents the amino acid position number
(or the grid box number along the path). The i, j values represent
any of the 20 amino acids.
The partition function, Z, of the peptide is obtained according
to [34].
Z~J  P
n
t~2
Ut J ð3Þ
where J
*=U1 ; J=column 111...1 ½  . (It is to be noted that in the
Flory notation, the J* matrix is given as J   ~t100...0s that
would assign alanine to the first residue of peptide. In the present
formulation, the choice of the J* matrix allows for the
acknowledgement of all of the 20 amino acids to be the first
residue).
The probability of having residue i at the t
th position and
residue j at the t+1
st position is determined by:
pt,tz1;i,j~
J U2 ...UtU
0
tz1 ...UnJ
Z
ð4Þ
Here, U0
tz1 is the matrix obtained by equating all elements of
Utz1 to zero except the ij
th. The formula given above in Eq. 4 is
used to calculate the probabilities of transition states. Here, we
keep the indices t and t+1, but they will be dropped in the
application to the Viterbi algorithm for simplicity of representation
with the understanding that each pair of sites has its own pij.
Determining the emission probabilities of the w2y
torsion angles. A fundamental requisite for favorable binding
of a peptide to the surface is that the torsion angles of the peptide
in the bound conformation should not be forced to have
energetically unfavorable w2y torsion angle values. The apriori
probabilities of the torsion angles are needed for this purpose. In
this section we explain the formation of these probabilities, called
the emission probabilities, and their incorporation into the Viterbi
algorithm as the observable variables.
Two sets of probabilities are needed for specifying the
conformation of the peptide. The first set gives the probabilities
of the torsion states determined by the angles wt2yt of the residue
at the t
th grid. The second set gives the probabilities for the torsion
angles yt2wt+1 of the dipeptide formed by residues at t
th and t+1
st
grids. The representation of the defined torsion angles are shown
in Figure 2. The wt2yt torsion angles of the residue at grid t can
select any of eleven regions, as explained below and shown in
Figure 3. The torsion angles yt2wt+1 of the succeeding residue can
choose the eleven torsion angles as explained below and shown in
Figure 4. Each dipeptide is capped at its N-terminus by an acetyl
group in order to define the wt angle.
The w and y angles of a residue cannot adopt all values due to
backbone intrinsic torsion propensities and attractive and repulsive
interactions of atoms that are in close proximity for certain
combinations of these two angles. Among the repulsive interac-
tions, steric hindrances resulting from the side groups are the most
pronounced. Hydrogen bonds are the most pronounced favorable
interactions. Depending on the type of the residue, these angles
show preferences for different regions on the Ramachandran map.
The frequency of occurrence of these regions for the twenty amino
acids can be obtained from the Protein Data Bank, PDB. An
examination of the frequency of occurrence of the regions for
neighboring units shows that there is strong dependence on
residue type [50,51].
Figure 2. Schematic representation of torsion angles of a
dipeptide. Only the backbone atoms of dipeptide are given and the
acetyl cap on the N-terminal is shown as ACE, for simplicity.
doi:10.1371/journal.pone.0010926.g002
Figure 3. The representation of eleven states on Ramachan-
dran map.
doi:10.1371/journal.pone.0010926.g003
Figure 4. The probability distribution of Yt2Wtz1 angles on
Ramachandran map.
doi:10.1371/journal.pone.0010926.g004
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data, irrespective of residue type shows that there are eleven major
isomeric torsion angle states. These are shown in Figure 3. We
number the regions from 1 to eleven according to the notation of
Reference [52] shown in Table 1.
In obtaining Figure 3, the non-redundant PDB Select database
of native proteins was used. There are 197,458 points on the
Ramachandran map obtained from the database. 96% of these
points fell on the eleven regions shown in Figure 3. The
remaining 4% of points were outside of these regions which are
known to correspond to strained conformations of the residues
resulting from long range perturbations. We ignored this set of
4%.
The probability of occurrence of a residue in any of the eleven
regions given above depends on the type of the library used. Since
we are interested in the denatured conformations of peptides, we
calculated the probabilities over a coil library that we constructed.
The coil library was downloaded from the website: http://www.
roselab.jhu.edu/coil/. The library contains fragments selected by
Dunbrack’s PISCES server according to the following criteria: less
than 20% sequence identity, better than 1.6 angstrom resolution,
and a refinement factor of 0.25 or better [51].
A given residue may be of type i 1ƒiƒ20 ðÞ at the t
th grid, and
may be in torsion-state m, which is one of the eleven regions shown
in Figure 3. The frequency of occurrence of wt2yt in torsion-states
m for the i
th type of residue was collected in a two dimensional
array, fi ,m ðÞ which is the normalized frequency that an amino
acid is of residue type i in torsion-state m. The singlet probability
bi,m that the a residue along the peptide is of type i having the
torsion-state m is
bi,m~
fi ,m ðÞ
P
m0
fi ,m0 ðÞ
ð5Þ
For a given i, bi,m is a column vector of eleven entries. In Figure 5,
bi,m values are given for GLY as an example.
The choice of the torsion state of the t
th residue places
restrictions on the choice of the torsion state of residue t+1 due to
the dependence of the torsion angle wt+1 on yt. The extent of this
dependence for all pairs of residues in the coil library is depicted in
Figure 4 where the joint probability distribution of yt2wt+1 is
presented. For uniformity of representation, we keep the same
eleven regions of yt2wt+1. In obtaining Figure 4, the non-
redundant PDB Select database of native proteins was used. There
are 955,679 points on the Ramachandran map obtained from the
database. 91% of these points fell on the eleven regions shown in
Figure 3. The remaining 9% of points were outside of these
regions. We ignored this set of 9%. The probabilities are
calculated over the coil library of http://www.roselab.jhu.edu/
coil/.
The probability bi,j,m that the residue j is in state m of yt2wt+1
space when the preceding residue is of type i is
bi,j,m~
fi ,j,m ðÞ
P
m0
fi ,j,m0 ðÞ
ð6Þ
For a given ij, bi,j,m is a column vector of eleven entries.
For each n grid box, the docked conformation of the dipeptides
is determined by AutoDock. Knowing the conformation leads to
the wt2yt and yt2wt+1 angles. Thus, the torsion-state of the angles
is determined. Equations 5 and 6 give the apriori probability of
observing the torsion-states. The product of the two probabilities,
bi,m and bi,j,m, is called the emission probability for the torsion
state of residue j when the preceding residue i is already
prescribed. In the Viterbi algorithm below, this is indicated as
bi,j. The index m will be removed for simplicity.
Implementation of the Viterbi Algorithm
We follow the notation of Reference [39] in our application of
the Viterbi algorithm.
We need the following definitions:
n: Number of residues of the peptide.
t: Grid number, 1ƒtƒn
m: Index identifying the torsion state, 1ƒmƒ11
S~ S1,S2,...,S20 fg The 20 natural amino acids set.
A~ a1,a2,...,a11 fg : The eleven torsion angle regions.
qt: The state of the t
th grid. For example qt~Si means that
the state of the t
th grid is the amino acid Si.
at: The torsion-state of the amino acid at the t
th grid.
P~ pij
  
: The transition probability, pij~Pr qtz1~SjD
 
qt~SiÞ.
b~ bi,j
  
: The emission probability, bi,j~Pr atz1~AjD
 
at~AiÞ
Table 1. Notation for the eleven states.
State Notation Desrcription
1 e9 Mirror image of the extended region e
2 e The extended regions, Q.0, y, 2+180u
3 aR Right-handed alpha helix
4 c Tight turn region
5 dR The right handed bridge region between two b-strands
6 dL Mirror image of the dR region
7 f Region observed mostly in residues preceding PRO
8 c9 Inverse tight turn region
9 aL Mirror image of aR
10 bs Extended beta sheet forming region
11 bp Region with extended polyproline-like helices
doi:10.1371/journal.pone.0010926.t001
Figure 5. The probability distribution of GLY Wt2Yt angles,
derived from coil library. The dipeptide is mostly observed in the 6
th
state; and the least observation occurs for state 7.
doi:10.1371/journal.pone.0010926.g005
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q1~Si ðÞ .
The sets S and A describe the structure of the model, P, b and p
describe the parameters.
Our intention is to determine arg max
S
Pr q1,q2,...,qnDa1, ð
a2,...,anÞ, meaning a peptide sequence made up of preferable
torsion angles and with high affinity to protein binding-site. The
algorithm is divided into two parts. Firstly, in the forward tracking
step, the algorithm finds max Pr q1,q2,...,qnDa1,a2,...,an ðÞ . The
forward tracking employs emission and transition probabilities.
Then the algorithm backtracks to determine an a1,a2,...,an that
realizes this maximum.
For an arbitrary position t and amino acid type i:
dt i ðÞ : The maximum probability of all ways to end in state Si
at grid t and have observed the torsion states a1,a2,...,at.
dt(i)~ max
q1,q2:::qt{1
Pr q1,q2,...,qt{1,qt~Si and a1,a2,...,at ðÞ ð 7Þ
where
d1(i)~Pr q1~S1 and a1 ðÞ ð 8Þ
then,
max
q1,q2,...,qn
Pr q1,q2,...,qn and a1,a2,...,an ðÞ ð 9Þ
is determined.
Initialization step.
d1 i ðÞ ~pibi a1 ðÞ ,1 ƒiƒ20 ð10Þ
d1 is 1620 array, keeping the binding affinity probabilities of each
amino acid for the 1
st grid box. pi is the initial probability of
binding of any 20 amino acids to the 1
st grid box and is a 1620
array. All entries of pi are chosen as unity to give equal chance for
selection of any 20 amino acids as the initial residue of the peptide.
The binding affinity and the corresponding torsion states are
determined by AutoDock. The choice of the first residue will
contain the information of its torsion angles from AutoDock,
leading to the knowledge of the emission probability bi a1 ðÞ which
is accounted for in Eq. 10.
Induction step.
dtz1 j ðÞ ~ max
1ƒiƒ20
dt i ðÞ pijbi,j atz1Dat ðÞ ,1 ƒtƒn{1,1ƒi,jƒ20ð11Þ
dtz1 is 1620 array, keeping the binding affinity and torsion angle
preference probabilities of each dipeptide for t+1
st grid.
Backtracking. For each grid box, the maximum probabilities
are kept in dt i ðÞarrays, as defined in the previous section by Eq.
11. Backtracking of those arrays leads to the determination of a
peptide sequence with a possible affinity to protein binding-site.
Initially, the last residue of the peptide sequence is determined
from the 20 entries of dn, the array of the last grid box. The
maximum entry of dn is selected, which determines the amino acid
residue qn.
We let
Jn~argmax
1ƒiƒ20
dn i ðÞ ð 12Þ
and choose qn~SJn. Thus, qn is the final state of the last residue of
the peptide.
The remaining qi, that is the amino acid types, for 1ƒtƒn{1
are found recursively by determining:
Jt~argmax
1ƒiƒ20
dt i ðÞ piJtz1 ð13Þ
and then putting qt~SJt. The backtracking method leads to a
peptide sequence with high affinity to the target protein surface.
Quantifying the peptide – Target protein Interaction.
The AutoDock software is used for validating the accuracy of the
solutions. The tertiary structure of the designed peptide is prepared
using HyperChem. The details of the procedures are given in Appendix
S2. The binding affinity calculation between the target protein and the
designed peptide was carried out by AutoDock.
Test of the Algorithm
Protein-tripeptide case studies. As a proof of concept, the
Viterbi algorithm is tested on five known protein-tripeptide
complexes. The aim is to demonstrate the feasibility and the
reliability of the algorithm.
The binding energy between the target protein and the peptide
designed by Viterbi are determined by the AutoDock program.
The inhibition constant Ki is also calculated by AutoDock. The
visualization of complexes is achieved by Accelerys Discovery
Studio 2.5 program [53].
The first complex is HIV-1 protease interacting with the
tripeptide Glu-Asp-Leu. The PDB accession number of this
complex is 1A30 [54]. This tripeptide is the smallest analogue of
HIV-1 transframe octapeptide (TFP) Phe-Leu-Arg-Glu-Asp-Leu-
Ala-Phe, which is known to be the most potent inhibitor of the
target protein. The inhibition of the protein with this peptide is
selective and specific.
The second complex is scytalidocarboxyl peptidase B protein
interacting with the tripeptide Ala-Ile-His (1S2K) [55]. The
protein is pepstatin-insensitive carboxyl peptidase from the
organism Scytalidium lignicolum. The crystal structure contains the
protein and the cleaved angiotensin II peptide: Ala-Ile-His. The
tripeptide is bound to the catalytic residues Gln-53 and Glu-136 of
the protein.
The other complex chosen is the signaling protein from goat
mammary gland (SPG-40) and the tripeptide Trp-Pro-Trp
(1ZBW) [56]. The protein plays role in signaling for reductive
remodeling of mammary gland. The remodeling is necessary after
cessation of lactation in female mammals. The protein is known to
interact with oligosaccharides; the binding enhances protein-
protein interactions. The tripeptide Trp-Pro-Trp sits at the active
site, to which oligosaccharides bind.
The peptide deformylase (PDF) from Enterococcus faecium
organism with Met-Ala-Ser tripeptide is another selected complex
(3G6N), to which the peptide design algorithm is applied [57]. E.
faecium are found in normal flora of the intestinal track, but the
Vancomycin (an antibiotic) resistant types of bacteria cause
infection commonly in hospitals and the strain is resistant to all
commercially available antibiotics. The PDF protein is essential
for bacterial growth, making it a potential drug target. The Met-
Ala-Ser motif is recognized by the active site of the protein.
The last test case for tripeptides is concanavalin A (Con A)
protein with Tyr-Pro-Tyr peptide (1HQW) [58,59]. The peptide is
determined to the best binding part out of ,1.4610
9 octapeptides.
A highly diverse phage library procedure is used to determine this
(7)
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indicates the importance of carbohydrate binding in various
biological processes. Consequently, inhibition of carbohydrate-
specific proteins is important for novel drug development. The
chemical synthesis of oligosaccharides is a sophisticated procedure
since protection of sugar monomers is complicated; peptides can
be used as ligands for such protein targets. The Tyr-Pro-Tyr
peptide is shown to inhibit binding of known monosaccharide
ligands to Con A.
Protein-heptapeptide case studies. In the second step of
our test, we applied the method to the design of heptapeptides
against Proteinase K, and HLA-B*2705 proteins. Both of these
proteins have known peptide ligands in the literature.
Proteinase K is a serine protease with broad specificity. The
PDB accession number of the inhibitor peptide Pro-Ala-Pro-Phe-
Ala-Ala-Ala in complex with the protein is 1P7V from the
organism Engyodontium album. The article about the crystal
structure and interaction details of this protein-peptide complex
has not yet been published.
HLA-B*2705 is a disease-associated human MHC class I allele
HLA-B27 subtype protein. The protein is the target for
nonapeptides. The self peptide sequence of this protein is Arg-
Arg-Lys-Trp-Arg-Arg-Trp-His-Leu. The copy number of this
peptide in ankylosing spondylitis patients is observed to increase
[60]. Viral peptide Arg-Arg-Arg-Trp-Arg-Arg-Leu-Thr-Val de-
rived from Epstein-Barr virus membrane has shown to have
affinity to HLA-B*2705 [61]. The glucagon receptor-derived
peptide Arg-Arg-Arg-Trp-His-Arg-Trp-Arg-Leu has also proven
to interact with HLA-B*2705 [62]. The PDB accession codes of
those 3 peptides in complex with HLA-B*2705 are 1OGT,
1UXS, 2A83.
Predicting a peptide for a protein with no known peptide
ligand. The Human Growth Hormone (HGH) is responsible for
linear growth in vertebrates via stimulation of skeletal and visceral
growth. The protein also plays a role in carbohydrate metabolism
and fat mobilization from tissues [63]. The PDB accession code of
the protein is 1HGU [64]. A crystal structure of the protein-
peptide complex is not available in PDB. Consequently, the most
possible binding site of the protein is determined by GNM.
Results
HIV-1 protease peptide
The Viterbi program designed the Trp-Tyr-Val tripeptide with
high binding affinity for the HIV-1 protease. The binding affinity
was calculated as 29.59 kcal/mol by AutoDock; the Ki value was
94.12 nanomolar. The binding affinity of the known inhibitor Glu-
Asp-Leu was determined by AutoDock as 27.66 kcal/mol; the Ki
value was 2.43 micromolar. The affinity terms are summarized in
the Table 2. The binding region of the peptides is shown in
Figure 6. Figure 6A indicates the complex formed by the HIV-1
protease with Glu-Asp-Leu, while Figure 6B indicates the complex
formed by the HIV-1 protease with Trp-Tyr-Val. As the figures
imply, both of the peptides bind to the same active-site on the
protein.
The HIV-1 protease is formed by 2 identical chains: chain A
and chain B. Glu-Asp-Leu interacts with the chain A residues Asp-
25, Gly-27 Ala-28, Asp-29, Asp-30, Met-46, Gly-48; and with the
chain B residues Arg-8, Asp-25, Val-82. The peptide makes five
Hydrogen bonds with Gly-27, Asp-29, Asp-30 and Gly-48 shown
in Figure 7A. A salt bridge is present between Asp-29 of the chain
A and Glu residue of the peptide. The sulfide atom of Met-46 from
the chain A makes a bond with the oxygen atom of Asp.
Trp-Tyr-Val interacts with the chain A residues Asp-25, Gly-27,
Ala-28, Asp-29, Asp-30, Gly-48, Pro-81, Val-82, Ile-84; and with
the chain B residues Asp-25, Gly-27, Ala-28, Ile-50, Thr-80, Pro-
81, Val-82, Ile-84. The peptide makes nine Hydrogen bonds with
Asp-25 of the both chains, Ile-50, Thr-80 and Val-82 as shown in
Figure 7B. There are 2 salt bridges between Asp-25 of the chain A
and the Trp residue of the peptide. Another 2 salt bridges are
present between Asp-25 of the chain B and Trp residue of the
peptide.
Scytalidocarboxyl peptidase B peptide
The Viterbi program designed the tripeptide Arg-Arg-Arg as
potential binder peptide for the scytalidocarboxyl peptidase B
protein. The binding affinity of this peptide was calculated as
212.96 kcal/mol; the Ki value was 315.78 picomolar. The known
inhibitor Ala-Ile-His binding affinity for the target protein was
determined as 25.33 kcal/mol; the Ki value was 124.38
Table 2. Binding energy; Ki values of HIV-1 protease peptides.
Peptide Binding Energy (kcal/mol) Ki
Glu-Asp-Leu 27.66 2.43 mM
Trp-Tyr-Val 29.59 94.12 nM
doi:10.1371/journal.pone.0010926.t002
Figure 6. HIV-1 protease peptide complexes. (A) Glu-Asp-Leu and HIV-1 protease. (B) Trp-Tyr-Val and HIV-1 protease.
doi:10.1371/journal.pone.0010926.g006
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binding region of the peptides is shown in Figure 8; Figure 8A
indicates the complex formed by the scytalidocarboxyl peptidase B
with Ala-Ile-His, while Figure 8B indicates the complex formed by
the scytalidocarboxyl peptidase B with Arg-Arg-Arg. As the figures
imply, both of the peptides bind to the same active-site.
Ala-Ile-His interacts with the residues Gln-53, Asp-57, Trp-67,
Glu-136, Phe-138, Glu-139, Glu-140, Cys-141, and Cys-148. The
peptide makes two Hydrogen bonds with Glu-139 as shown in
Figure 9A. p{p stacking between Trp-67 and His residues of the
peptide is present. There is a salt bridge between Glu-139 and Ala
residue of the peptide. Sulfide atom and aromatic ring interaction
is present between residues Cys-141 and His; Cys-148 and His. S-
O bonding is present between the residues: Cys-141 and Ala; Cys-
148 and Ala.
Arg-Arg-Arg interacts with the residues Trp-6, Trp-39, Gln-53,
Asp-57, Tyr-59, Asp-65, Trp-67, Glu-69, Glu-73, Glu-136, Phe-
138, Glu-139, Glu-140, and Cys-141. The peptide makes fifteen
Hydrogen bonds with the residues Asp-57, Tyr-59, Glu-69, Glu-
73, Glu-136, Glu-139, and Glu-140 as indicated in Figure 9B. p-
cation interactions are observed between Phe-138 and Arg-1
residue of the peptide; Trp-39 and Arg-3 residues. There are salt
bridges Glu-69 and Arg-1; Glu-140 and Arg-1; Glu-136 and Arg-
3; Asp-65 and Arg-3; also an internal salt bridge between Arg-1
and Arg-3 residues of the peptide. Arg-1 interacts with Cys-141
through S-O bonding.
SPG-40 peptide
The Viterbi program designed the tripeptide Trp-Tyr-Tyr as
the sequence with possible binding affinity to SPG-40. The
binding affinity of this peptide was calculated as 210.97 kcal/mol;
the Ki value was 9.04 nanomolar. The known inhibitor Trp-Pro-
Trp binding affinity for the target protein was determined by
AutoDock as 29.10 kcal/mol; the Ki value was 215.27 nanomo-
lar. The affinity terms are summarized in Table 4. The binding
region of the peptides is shown in Figure 10. Figure 10A indicates
the complex formed by SPG-40 with Trp-Pro-Trp, while
Figure 10B indicates the complex formed by SPG-40 with Trp-
Tyr-Tyr. As the figures imply, both of the peptides bind to the
active-site of the protein. Trp-Pro-Trp interacts with the residues
Trp-10, Arg-14, Asn-79, Thr-267, and Glu-269. The peptide
makes two Hydrogen bonds with Asn-79 shown in Figure 11A.
There is a salt bridge between Glu-139 and Ala residue of the
peptide.
Trp-Tyr-Tyr interacts with the residues Trp-10, Arg-14, Cys-
20, Phe-37, Trp-78, Asn-79, Asp-186, Arg-242, Glu-269, Ile-272,
Trp-331, Asp-334, and Leu-335. The peptide makes six Hydrogen
bonds with the residues Arg-14, Arg-242, and Glu-269 shown in
Figure 11B. p{p stacking is observed between Trp-10 and Trp-1
residue of the peptide and Phe-37 and Trp-1 residues. p- cation
interactions are observed between Trp-78 and Tyr-2; Trp-10 and
Trp-1; also between Tyr-2 and Trp-1 residues of the peptides;
Tyr-2 and Tyr-3 residues of the peptides. There are salt bridges
between Glu-269 and Trp-1. There exists aromatic ring and
sulfide interaction between Cys-20 and Tyr-2.
PDF peptide
The Viterbi program designed Val-Trp-Trp as peptide with
possible binding affinity to PDF. The binding affinity of this
peptide was calculated as 29.52 kcal/mol and the Ki value was
105.71 nanomolar. The known inhibitor Met-Ala-Ser binding
affinity for the target protein was determined as 28.07 kcal/mol.
The Ki value was 1.21 micromolar. The affinity terms are
summarized in Table 5. The binding region of the peptides is
shown in Figure 12. Figure 12A indicates the complex formed by
the PDF with Met-Ala-Ser, while Figure 12B indicates the
complex formed by the PDF with Val-Trp-Trp. As the figures
imply, both peptides bind to the active-site on the protein. The
Fe
+2 ion in the active site is shown with CPK representation.
Met-Ala-Ser interacts with the residues Gly-57, Val-59, Gly-60,
His-76, Gly-113, Leu-115, Tyr-150, His-157, His-161, and Phe-
167. The peptide makes no Hydrogen bonds with the protein,
Figure 13A. A sulfide atom and aromatic ring interaction occurs
between the residues His-76 and Met; Tyr-150 and Met; His-157
and Met; His-161 and Met; Phe-167 and Met.
Val-Trp-Trp interacts with the residues Met-4, Gln-45, Gly-57,
Gly-58, Gly-60, Leu-108, Glu-110, Gly-111, Glu-112, Gly-113,
Figure 7. Detailed analysis of HIV-protease peptide complexes. Hydrogen bonds are indicated with green lines. (A) Glu-Asp-Leu and HIV-1
protease. (B) Trp-Tyr-Val and HIV-1 protease.
doi:10.1371/journal.pone.0010926.g007
Table 3. Binding energy; Ki values of scytalidocarboxyl
peptidase B peptides.
Peptide Binding Energy (kcal/mol) Ki
Ala-Ile-His 25.33 124.38 mM
Arg-Arg-Arg 212.96 315.78 pM
doi:10.1371/journal.pone.0010926.t003
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187. The peptide makes four Hydrogen bonds with Gly-111, Gly-
113 and Tyr-150 as shown in Figure 13B. There are internal salt
bridges between Val-1 and Trp-3 residues of the peptide. There is
an aromatic ring and sulfide atom interaction between the residue
pairs Cys-114 and Trp-3, Met-4 and Trp-3, Met-166 and Trp-3.
Con A peptide
The Viterbi program designed the tripeptide Gly-Ala-Tyr for Con
A. The binding affinity of this peptide was calculated as 25.70 kcal/
mol; the Ki value was 65.83 micromolar. The known inhibitor Tyr-
Pro-Tyr binding affinity for the target protein was determined as
25.70 kcal/mol. The Ki value was 144.38 micromolar. The affinity
terms are summarized in Table 6. The binding region of the peptides is
shown in Figure 14;Figure 14a indicates the complex formed by the Con
A with Tyr-Pro-Tyr, while Figure 14b indicates the complex formed by
the Con A with Gly-Ala-Tyr. As the figures imply, both peptides bind
to the active-site of the protein. Tyr-Pro-Tyr interacts with the residues
Thr-15, Ser-21. The peptide makes one Hydrogen bond with
Thr-15.
Gly-Ala-Tyr interacts with the residues Thr-11, Tyr-12, Pro-13,
Thr-15, Asp-16, His-205, Pro-206, and Arg-228. The peptide
makes seven Hydrogen bonds with Thr-11, Tyr-12, Asp-16,
Pro-206 and Arg-228. p{p stacking is probable between Tyr-12
and Tyr residues.
Proteinase K peptide
The Viterbi program designed the Trp-Tyr-Tyr-Tyr-Tyr-
Tyr-Tyr heptapeptide with possible binding affinity to Protein-
ase K. The binding affinity of this peptide was calculated as
211.59 kcal/mol. The Ki value was 3.22 nanomolar. The
known inhibitor Pro-Ala-Pro-Phe-Ala-Ala-Ala binding affinity
for the target protein was determined as 28.52 kcal/mol; the Ki
v a l u ew a s5 6 9 . 8 6n a n o m o l a r .T h ea f f i n i t yt e r m sa r es u m m a -
rized in Table 7. Both peptides bind to the active-site on the
protein.
Pro-Ala-Pro-Phe-Ala-Ala-Ala interacts with the residues Asn-
67, His-69, Asn-99, Gly-100, Tyr-104, Leu-133, Gly-134, Gly-
135, Gly-136, Ala-158, Gly-160, Asn-161, Asn-162, Trp-212, Ile-
220, Ser-221, Thr-223, Ser-224, and Met-225. The peptide makes
one Hydrogen bond with Gly-102. There exist a pi-cation
interaction between Tyr-104 and Pro-1. A sulfide atom and
aromatic ring interaction is observed between Cys-73, Met-225
residues and Phe-4. The sulfide atom oxygen interaction is present
between Cys-73 and Ala-7. The stacking of ring structures is
observed for His-69 and Phe-4.
Figure 8. Scytalidocarboxyl peptidase B peptide complexes. (A) Ala-Ile-His and scytalidocarboxyl peptidase B. (B) Arg-Arg-Arg and
scytalidocarboxyl peptidase B.
doi:10.1371/journal.pone.0010926.g008
Figure 9. Detailed analysis of scytalidocarboxyl peptidase B peptide complexes. Hydrogen bonds are indicated with green lines. (A) Ala-
Ile-His and scytalidocarboxyl peptidase B. (B) Arg-Arg-Arg and scytalidocarboxyl peptidase B.
doi:10.1371/journal.pone.0010926.g009
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67, His-69, Asn-99, Ser-101, Gly-102, Gln-103, Tyr-104, Leu-
133, Gly-134, Ala-158, Gly-160, Asn-161, Asn-162, Tyr-169, Ser-
170, Ala-172, Trp-212, Ile-220, and Ser-224. The peptide makes
three Hydrogen bonds with Gln-103, Ser-170 and Asn-161. A
sulfide atom and aromatic ring interaction is observed between
Cys-73, Met-225 residues and Trp-1, Tyr-2, Tyr3 residues of the
peptide. p{p stacking is observed between His-69, Trp-212 and
Trp-1; His-69 and Tyr-2; Tyr-169 and Tyr-3; Phe-192 and Tyr-4;
Tyr-104 and Tyr-6; also between Tyr-5 and Tyr-6 of the peptide.
A pi-cation interaction is present between His-69 and Trp-1.
HLA-B*2705 peptide
The Viterbi program designed the Trp-Arg-Trp-Trp-Lys-Tyr-
Tyr heptapeptide for HLA-B*2705. The binding affinity of this
peptide was calculated as 28.97 kcal/mol; the Ki value was
265.82 nanomolar. The known inhibitors Lys-Trp-Arg-Arg-Trp-
His-Leu, Arg-Trp-His-Arg-Trp-Arg-Leu, Arg-Trp-Arg-Arg-Leu-
Thr-Val binding affinity for the target protein were determined by
AutoDock as 26.84, 27.21, and 28.52 kcal/mol, respectively.
The affinity terms are summarized in Table 8. Both peptides bind
to the active-site on the protein.
Lys-Trp-Arg-Arg-Trp-His-Leu interacts with residues Arg-62,
Ile-66, Lys-70, Thr-73, Asp-77, Tyr-99, His-114, Lys-146, Trp-
147, Val-152, Gln-155, Lue-156, and Tyr-159. The peptide makes
nine Hydrogen bonds with Ile-66, Lys-70, Asp-77, Tyr-84, Tyr-99,
Thr-143, Trp-147, and Gln-155. There exist pi-cation interactions
between Lys-146 and His-6; Lys-1 and Trp-2; Tyr-159 and Lys-1;
and Tyr-99 and Lys-1. A salt-bridge is present between Asp-77
and Arg-3. A sulfide atom and aromatic ring interaction is
observed between Cys-164, Met-5 residues and Trp-2. Stacking of
ring structures is observed for Tyr-99 and Trp-2; Tyr-159 and
Trp-2; Trp-2 and Trp- 7 in the peptide; Trp-147 and Trp-5; Trp-
133 and Trp-5; Trp-147 and His-6.
Trp-Arg-Trp-Trp-Lys-Tyr-Tyr interacts with the residues Ala-
69, Thr-73, Glu-76, Thr-80, Arg-83, His-114, Lys-146, Trp-147,
Ala-150, Val-152, Gln-155 and Leu-156. The peptide makes three
Hydrogen bonds with Thr-80, Arg-83 and Gln-155. A sulfide atom
and aromatic ring interaction is observed between Cys-67 and Trp-
4 residueofthepeptide.p{p stacking isobserved between Trp-147
and Trp-1; His-114 and Trp-3; Trp-147 and Trp-3; Tyr-99 and
Trp-3; Trp-133 and Trp-3; Trp-147 and Tyr-6.
HGH peptide
The Viterbi program designed Trp-Glu-Leu-Met-Phe-Phe-Tyr
heptapeptide for HGH. The binding affinity of this peptide was
calculated as 28.05 kcal/mol; the Ki value was 1.25 micromolar.
The affinity terms are summarized in Table 9.
Trp-Glu-Leu-Met-Phe-Phe-Tyr interacts with the residues Met-
14, His-21, Gln-22, Phe-25, Arg-64, Glu-65, Gln-66, Thr-175,
Arg-178, Cys-182, and Cys-189. The peptide makes five
Hydrogen bonds with Arg-64 and Arg-178. There exist a pi-
cation interaction between Arg-178 and Tyr-7. A sulfide atom and
aromatic ring interaction is observed between Met-170 and Trp-1;
His-18 and Met-4; Met-14, Cys-182, Cys-189 and Phe-5; Met-14,
Cys-182, Cys-189 and Phe-6; Cys-182, Cys-189, Met-14 and Tyr-
7. Sulfur – oxygen interactions exist between Ser-188 and Met-4;
Cys-189 and Met-4; Cys-182, Cys-189 and Phe5; Cys-182, Cys-
189 and Phe-6; Cys-182 and Tyr-7. Stacking of ring structures is
observed for His-21 and Trp1; Phe-25 and Trp-1; His-18 and
Trp-1; His-18 and Phe-5.
Discussion
The Viterbi algorithm is successful in predicting tripeptides to
the five proteins. The binding affinities of the designed tripeptides
are all superior to the binding affinities of their known tripeptide
ligands. The comparison is made by using the affinities given by
the AutoDock. The method is also successful in predicting
heptapeptides to the two proteins, proteinase K and HLA*B2705.
The method was able to determine a better potential binding
peptide for these two proteins.
The ability of our algorithm for de novo peptide design is proven
for the HGH protein case-study. The binding affinity of the
peptide is comparably better than some known peptide inhibitor
affinities for their own target proteins.
The binding surfaces of all target proteins, except Con A, have
both hydrophilic and hydrophobic residues. The Con A binding
Table 4. Binding energy; Ki values of SPG-40 peptides.
Peptide Binding Energy (kcal/mol) Ki
Trp-Pro-Trp 29.10 215.27 nM
Trp-Tyr-Tyr 210.97 9.04 nM
doi:10.1371/journal.pone.0010926.t004
Figure 10. SPG-40 peptide complexes. (A) Trp-Pro-Trp and SPG-40. (B) Trp-Tyr-Tyr and SPG-40.
doi:10.1371/journal.pone.0010926.g010
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that a binding surface with both hydrophilic and hydrophobic
residues could lead to a potential binder peptide design by our
method. A surface exposed to water, with all hydrophilic residues,
may not lead to very potent peptide designed by the Viterbi
algorithm. This may be due to low number of residues in each grid
box, since there is no cavity on the Con A surface. All other
protein targets described in this paper have specific cavities as the
binding surfaces. Consequently, the number of protein residues
interacting with amino acids/dipeptides is low for the binding
surfaces that are highly exposed to solvent. Balanced number of
hydrophilic-hydrophobic residues in a grid box leads to more
specific interactions. The specific interactions lead to design of a
specific peptide with affinity to the selected protein surface.
The HIV-1 protease binding surface has 24 net charges, 50%
of residues that form the surface is hydrophobic; the Trp-Tyr-Val
peptide designed for this surface has two hydrophobic and one
hydrophilic residues. The hydrophobic residue number is in
harmony with the number of hydrophobic residues of the protein
(chain A: Ile-50, Pro-81, Val-82, Ile-84; chain B: Pro-81, Val-82,
Ile-84). The hydrophilic residue Tyr, which sits in the middle of
the peptide, is in close proximity to the polar and basic residues of
the protein surface. The known peptide of this protein has one
hydrophobic and two basic residues; the only hydrophobic residue
is close to Val-82 of chain B. The known peptide Glu-Asp-Leu
makes interactions with only the hydrophilic and the charged
residues; while the designed peptide also interacts with the
hydrophobic residues of the binding pocket. Although the number
of the intermolecular hydrogen bonds and the salt-bridges are the
same for the protein-known peptide and the protein-designed
peptide; the electrostatic compatibility between the protein and the
designed peptide is more appropriate.
The Scytalidocarboxyl peptidase B binding surface has 24 net
charges, 25% of residues is hydrophobic; the designed peptide
Arg-Arg-Arg has +3 net charges. There are seven basic residues in
the binding pocket; so the designed peptide stabilizes itself by
electrostatic complementarity and the salt bridge formation. The
known peptide Ala-Ile-His has two hydrophobic and one acidic
residues; this peptide can interact with only 50% of the basic
residues of the binding region. The designed peptide size is larger
than that of the Ala-Ile-His peptide and the designed peptide also
contains more positive charge. The tripeptide Arg-Arg-Arg makes
a fine interaction with protein surface. The designed peptide
makes three times more hydrogen bonds with the protein, when
compared to the known peptide-protein interaction. The p
interactions and the sulfur atom bonds are observed in both the
protein-known peptide and the protein-designed peptide systems.
The electrostatic compatibility between the protein and the
designed peptide is more appropriate.
The SPG-40 protein binding region has no net charge, since it
contains one acidic and one basic residues. 20% of residues is
hydrophobic; the designed Trp-Tyr-Tyr peptide has two hydro-
philic and one hydrophobic residues. The only hydrophobic
residue Trp is surrounded by six hydrophobic residues; four of
those hydrophobic amino acids have aromatic ring in their side
chains enabling the p interactions. Our method designed a peptide
with two Tyr residues, which are similar to saccharide monomers.
Also Trp residue of the designed peptide has aromatic ring
structure that is also observed in saccharides. The similarity is
important since the binding molecule of the target protein is
oligosaccharides. The known peptide is made up of all
hydrophobic residues. The designed peptide makes more hydro-
gen bonds with the protein, compared to the known peptide. The
p interactions and the sulfur atom bonds are observed only in the
protein-designed peptide.
The peptide deformylase binding surface has no charge, 33% of
residues is hydrophobic; the designed Val-Trp-Trp peptide is
made up of all hydrophobic residues. The known peptide consists
of two hydrophobic and one hydrophilic residues. The known
peptide makes five sulfide – aromatic ring interactions; while the
designed peptide makes five sulfide – aromatic ring interactions
and four Hydrogen bonds.
The Con A binding surface is exposed to water with no charge;
the peptide Gly-Ala-Tyr has two hydrophilic and one small
hydrophobic residues. The known peptide is also made up of two
hydrophilic and one hydrophobic residues. Both of the peptides
have their hydrophilic residue as the 2
nd amino acid. The designed
Figure 11. Detailed analysis of SPG-40 and peptide complexes. Hydrogen bonds are indicated with green lines. (A) Trp-Pro-Trp and SPG-40.
(B) Trp-Tyr-Tyr and SPG-40.
doi:10.1371/journal.pone.0010926.g011
Table 5. Binding energy; Ki values of PDF peptides.
Peptide Binding Energy (kcal/mol) Ki
Met-Ala-Ser 28.07 1.21 mM
Val-Trp-Trp 29.52 105.71 nM
doi:10.1371/journal.pone.0010926.t005
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peptide is more distant to the surface. The Ala and Gly residues
give flexibility to the peptide with their small side-chains. Our
method kept the Tyr residue, which is similar to saccharide
monomers. As stated in the case of SPG-40, the similarity to
saccharides is important since the binding molecule of this target
protein is also oligosaccharides.
The proteinase K binding surface has +1 net charge, 20% of
residues that form the surface is hydrophobic; the 14% of residues
of the designed peptide Trp-Tyr-Tyr-Tyr-Tyr-Tyr-Tyr is hydro-
phobic. The Asn-161 residue of protein plays role in formation of
hydrogen bond with both the known and the designed peptides.
The residues Cys-73, Met-225 form stable sulfide aromatic ring
interactions with both the known and the designed peptides; but
the number of interactions formed are higher for the Viterbi
designed peptide. The aromatic ring stacking number is superior
for the designed peptide, since it has more residues with side-
chains containing ring structures when compared to the known
peptide sequence Pro-Ala-Pro-Phe-Ala-Ala-Ala.
The HLA-B*2705 protein binding surface is made up of 44%
by hydrophobic residues. Both the designed and the self-peptide
have 3 hydrophobic residues, which are able to make interactions
with the hydrophobic residues of binding surface. The self-peptide
net charge is +3; the designed peptide charge is +2. The algorithm
is successful to keep Lys and Arg residues, which are known to play
major role in HLA-B*2705 binding. The residue Gln-55 is
observed to play a role in hydrogen bonding for both the known
and the designed peptide. The designed peptide makes three net
hydrogen bonds, while the known peptide makes only two bonds.
The HGH binding region is made up of hydrophobic residues
by 18%. The net charge of the surface is +2 and the net charge of
the designed peptide is 21. Consequently, there exist an
electrostatic complementarity between the target protein and the
designed peptide. There exist two Cys and one Met residues on
protein binding site, which are potential stabilizing residues of
peptide binding. The designed peptide also has a Met residue,
which makes interactions with the sulfur atom on its side-chain.
Numerous sulfur - aromatic ring, sulfur – oxygen interactions are
observed due to the Cys and Met residues of both the peptide and
the protein. The Trp and Phe residues of the peptide enable
stacking of aromatic rings.
The detailed analysis of the designed peptide interactions and
comparison of those peptides with the known peptides indicate
that our method is able to detect the requirements of binding
surface; such as hydrophilicity, electrostatic compatibility, aromat-
ic interactions, sulfur atom and its interactions.
The residues Trp, Tyr and Val are highly favored on the
designed peptides. The binding energy of dipeptides containing
Figure 12. PDF peptide complexes. (A) Met-Ala-Ser and PDF. (B) Val-Trp-Trp and PDF.
doi:10.1371/journal.pone.0010926.g012
Figure 13. Detailed analysis of PDF and peptide complexes. Hydrogen bonds are indicated with green lines. (A) Met-Ala-Ser and PDF. (B) Val-
Trp-Trp and PDF.
doi:10.1371/journal.pone.0010926.g013
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Consequently the transition probabilities of those dipeptides are
favored. This may be the reason for high occurrence of those
residues in the designed peptide sequences. The conservation of
Trp may also be due to the formation of stacking and consequent
stabilization. When the protein – designed peptide complexes are
analyzed in detail, it is obvious that Trp residues form high
number of stacking due to its aromatic ring; this stabilizes the
formed complex. The same observation applies to Val for
hydrophobic regions; since it has a smaller side-chain compared
to other hydrophobic residues - except Ala -; the amino acid is able
to interact with small hydrophobic cavities. The HIV-1 protease,
SPG-40, HLA-B*2705 and Con A proteins have Trp and Tyr
residues on their own inhibitory peptides; and proteinase K
protein binding surface contains Trp, Phe and His residues on its
binding surface. Nature seems to protect interactions containing
amino acids with aromatic side-chains; our methodology also
conserves those residues. A recent study of London et al. [28]
reveals that few hot-spots on the peptide are responsible of the
protein binding. The hot-spot residues are enriched in Phe, Leu,
Trp, Tyr and Ile. Out of 36 amino acids of the peptides
determined by VitAL, the 21 are Trp and Tyr residues. Also the
peptide for the HGH protein has two Phe and one Leu residues.
Our algorithm designed a positively charged peptide for the
negatively charged scytalidocarboxyl peptidase B protein surface.
The method also conserved the Lys and Arg residues for HLA-
B*2705 protein, which are known the play major role in peptide
binding to this surface. This proves that our method not only
favors the aromatic and the hydrophobic interactions, but also the
electrostatic complementarity.
The only case that the method failed to determine an
outstanding binder peptide is for the Con A protein case. The
surface of this protein is highly exposed to water, as stated before.
Consequently, we may state that our algorithm works best for
cavities on protein surfaces, with both hydrophilic and hydropho-
bic residues present.
The study of 103 protein-peptide complexes by London et al.
[28] showed that most peptides do not alter the target protein
conformation minimizing the entropic cost of binding. This
statement is supportive for our studies, since the protein
conformation is kept rigid and the peptide is relaxed free to
change conformation in AutoDock runs. London et al. also
indicates that peptides of length 6–11 are observed to have coiled
conformation generally. The peptides designed by VitAL are
observed to have coiled conformation when bound to their target
protein.
The peptide design based on a pre-determined binding surface
is shown to be successful on the case-studies. Peptides are modeled
as sequences of Markov chains where the states defined for each
residue are dependent on the states of the neighboring residues
along the chain. This assumption allows for the application of the
RIS formalism to calculate the binding probability and confor-
mational properties of the peptides. Here, we used a knowledge-
based approach to determine the statistical weights of the torsion
angle states of the 20 amino acids and the dependences of the
statistical weights on the neighboring residues. The partition
function for a given peptide is determined using the RIS
multiplication of the statistical weight matrices. The Viterbi
algorithm is implemented to our method in order to determine a
potential binding peptide using the probability values from RIS
multiplication scheme. For the Viterbi Algorithm, the binding
probabilities are set as the transition state probabilities, while the
torsion state probabilities are set as the emission probabilities. The
peptide design; the binding affinity of the designed peptide; the
peptide – protein interactions are analyzed in detail. The
importance of the binding surface selection is highlighted; a
binding path with no cavity and made up of all hydrophilic
residues was shown to be not very suitable for determination of a
Figure 14. Con A peptide complexes. (A) Tyr-Pro-Tyr and Con A. (B) Gly-Ala-Tyr and Con A.
doi:10.1371/journal.pone.0010926.g014
Table 6. Binding energy; Ki values of Con A peptides.
Peptide Binding Energy (kcal/mol) Ki
Tyr-Pro-Tyr 25.24 144.38 mM
Gly-Ala-Tyr 25.70 65.83 mM
doi:10.1371/journal.pone.0010926.t006
Table 7. Binding energy; Ki values of Proteinase K peptides.
Peptide Binding Energy (kcal/mol) Ki
Pro-Ala-Pro-Phe-Ala-Ala-Ala 28.52 569.86 nM
Trp-Tyr-Tyr-Tyr-Tyr-Tyr-Tyr 211.59 3.22 nM
doi:10.1371/journal.pone.0010926.t007
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determine peptide according to the specific properties of the
binding surface.
Haack et al. [65] indicated that the introduction of D-amino
acids can significantly increase resistance to proteases and thus
improve the potential use of peptides as therapeutic agents. For
further improvements on VitAL we aim to add D-forms of amino
acids into our library.
The algorithm requires O(mn) memory and O(mn
2) time to
run; where n is the peptide length and m is 20 - the number of
states- [39]. The program details are given in Appendix S3. The
time-consuming part for our methodology is the docking process.
The Viterbi algorithm works efficiently to determine a single
peptide is superior to other possible peptides, i.e. the most possible
peptide sequence. The 1-best and posterior algorithms may also be
employed to determine de novo peptide sequences, which have the
same occurrence probability [42].
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